Earnings wrap: Brookdale, Cumberland

Senior living giant cuts guidance; drug marketer's profits slip on lower sales
Aug 5, 2015 2:12 PM

InvisionHeart joins CET Life Sciences Center

Cardiac technology company InvisionHeart is the newest tenant at the CET Life Sciences Center, a partnership between Cumberland Pharmaceuticals, Vanderbilt University and the state of Tennessee.

"We are very pleased to welcome InvisionHeart to the growing community of health care entrepreneurs at the CET Life Sciences Center," A.J. Kazimi, Cumberland Pharmaceuticals CEO, said in a release. "We are committed to helping build the biomedical segment of the health care industry in Middle Tennessee."

InvisionHeart raised $1.9 million last year and most recently hired Melanie Varin, formerly with GE Healthcare, to lead commercialization efforts. The company's devices allow health care providers to read and transmit real-time electrocardiogram tracings to cardiologists. The company is the sixth tenant at the CET Life Sciences Center.

"We are delighted to join the community of companies at the CET Life Sciences Center,” said Josh Nickols, President and CEO of InvisionHeart. “Our office is a great fit for the needs of a collaborative, team-oriented layout, as well as being suited to the requirements of a controlled manufacturing location. The center is conveniently located near the resources of Vanderbilt University, the Nashville Entrepreneur Center, and other healthcare companies that have supported development of the InvisionHeart ECG technology. This location and the second half of 2015 will be vitally important as we prepare for the introduction of our products to the market."

May 20, 2015 3:00 PM

Earnings wrap: Brookdale, Diversicare, Cumberland

Senior living facility company misses; acquisitions boost skilled nursing provider
May 8, 2015 6:53 AM

Cumberland Pharmaceuticals wraps up '14 in the black

Revenues rise 15%, company updates development pipeline status
Mar 4, 2015 6:51 AM

Cumberland Pharmaceuticals developing new respiratory drug

Cumberland Pharmaceuticals has received approval to continue development on a new drug to treat respiratory disease.

The Nashville company has completed manufacturing and received clearance from the U.S. Food and Drug Administration to complete a phase II study of Boxaban, which could be used to treat aspirin-exacerbated respiratory disease.

In 2011, Cumberland announced the acquisition of the ifetroban program in collaboration with Vanderbilt University and Cumberland Emerging Technologies.

"The manufacture of the oral capsule formulation and initiation of the AERD clinical development program by Cumberland represents a significant milestone for our collaboration," Dr. John Oates (pictured), professor of medicine and pharmacology at Vanderbilt University, said in a release.

Shares of Cumberland (Ticker: CPIX) were up half a percent to $5.88 Wednesday morning. In the last six months, they're up 20 percent.

Feb 11, 2015 12:10 PM

Cumberland Pharmaceuticals patent challenges continue

Indian company files against four acetaminophen overdose patents
Dec 22, 2014 1:00 PM

Earnings wrap: AmSurg, Cumberland

Surgery center chain buys two physician practices; drug marketer continues profitable '14
Nov 5, 2014 6:40 AM

Earnings wrap: Cumberland, Delek Logistics

Drug marketer lands new line of credit; higher wholesale margins lift pipeline owner
Aug 6, 2014 6:52 AM

Nashville health care's global reach

Health care is powerful and very visible force in Middle Tennessee, where it accounts for one out of every eight jobs. But entities based in and around Nashville also have an international reach that touches millions of people on just about every continent. Here, from our new Healthier magazine out new, are just a few data points.

Jun 10, 2014 5:32 AM

Earnings wrap: Emdeon, Cumberland

Transaction processor sees sales grow but operating income dip; drug marketers launched two new drugs, joint R&D venture during quarter
May 14, 2014 7:00 AM